Drug Profile
SB 1
Latest Information Update: 24 Oct 2021
Price :
$50
*
At a glance
- Originator Millennium Pharmaceuticals
- Developer Eli Lilly and Company; Takeda Oncology
- Class Ischaemic heart disorder therapies; Peptides
- Mechanism of Action GPIIb-IIIa antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Thrombosis
Most Recent Events
- 30 Apr 1998 Discontinued-Preclinical for Thrombosis in USA (Unknown route)
- 16 Feb 1998 No-Development-Reported for Thrombosis in USA (Unknown route)
- 02 May 1995 New profile